US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.44 against a street estimate of 0.27 — a beat of 63.0%.
Analysts rate Pacira BioSciences, Inc. a buy (4 buy, 2 hold, 1 sell out of 7) with an average price target of $29.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.90% |
| Doma Perpetual Capital Management LLC | 6.97% |
| Vanguard Portfolio Management, LLC | 6.27% |
| Dimensional Fund Advisors, Inc. | 5.28% |
| D. E. Shaw & Co LP | 4.89% |
| State Street Corp | 4.82% |
| Renaissance Technologies Corp | 4.58% |
| Vanguard Capital Management, LLC | 4.48% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PACIRA BIOSCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product sales Q2 2026: $190.5 million (vs. $180.3 million Q2 2025) — 5.6% inc | 2026-08-04 |
| Results announced · Q3 2026 PACIRA BIOSCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Q2 2026 revenue: $192.4 million (6% YoY growth vs. $181.1 million in Q2 2025) | 2026-08-04 |
| Material agreement · Q2 2026 PACIRA BIOSCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Total deal value: Up to $140 million ($70 million upfront + up to $70 million in cont | 2026-06-30 |
| Board / officer change · Q2 2026 PACIRA BIOSCIENCES, INC. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company held 2026 Annual Meeting of Stockholders on June 9, 2026 in Pars | 2026-06-11 |
| Quarterly report · Q1 2026 PACIRA BIOSCIENCES, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Net product sales Q1 2026: $177.4 million (vs. $167.6 million Q1 2025) – 5.8% increase | 2026-04-30 |
| Results announced · Q2 2026 PACIRA BIOSCIENCES Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $177.4 million (5% increase vs Q1 2025's $168.9 million) • GA | 2026-04-30 |
| Annual report FY2025 PACIRA BIOSCIENCES, INC. — FORM 10-K SUMMARY HEADLINE NUMBERS • Fiscal year ended December 31, 2025 • Company trades as PCRX on Nasdaq Global Select | 2026-02-26 |
| Quarterly report · Q3 2025 PACIRA BIOSCIENCES, INC. — Q3 2025 10-Q SUMMARY HEADLINE NUMBERS • Q3 2025 Net Product Sales: $178.0 million (vs. $167.7 million in Q3 2024), up 6.1 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pacira BioSciences, Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.